Community curated by people like you

Colon cancer stories

Oct 9, 2026

FDA approves atezolizumab with chemotherapy for stage III colon cancer

The FDA has approved atezolizumab (Tecentriq) in combination with chemotherapy as adjuvant treatment for adult and pediatric patients aged 2 years or older with stage III mismatch repair-deficient colon cancer.

Oct 9, 2026·2 sources

00

Top claims

▪The FDA's approval of atezolizumab for pediatric patients is justified despite the lack of pediatric trial participants
▪The FDA approved a subcutaneous formulation, atezolizumab and hyaluronidase-tqjs, for adult and pediatric patients aged 12 years and older weighing at least 40 kg
▪The recommended intravenous atezolizumab dose for pediatric patients is 10 mg/kg up to 840 mg every 2 weeks, or 15 mg/kg up to 1200 mg every 3 weeks

Topics

Cancer treatment breakthroughs FDA drug approval Immunotherapy

Related entities